Pay in 4 interest-free payments of $6.20 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
The study found that a weekly 2.4 mg dose of semaglutide reduced the risk of major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) by approximately 20% over three years compared to a placebo
Primary Respondent Breakdown: By Designation: C-level Primaries (32%), Director Level (31%), Others (37%) By Region: North America (32%), Europe (30%), Asia-Pacific (28%), Rest of World (10%) Market Size Estimation Global market valuation was derived through revenue mapping and prescription volume analysis
Congenital erythrocytic
Liraglutide as Add-On to Sodium-Glucose Co-Transporter-2 Inhibitors in Patients with Inadequately Controlled Type 2 Diabetes: LIRA-ADD2SGLT2i, a 26-Week, Randomized, Double-Blind, Placebo-Controlled Trial
